MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
Items 301–400 of 615
Huang, A. Y., Zhou, Z., Talukdar, M., Enyenihi, L., Miller, M. B., Chhouk, B., Rosen, I., Zheng, M., Zhou, M., Yang, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.040 · Cited by 15
“Drugs targeting such genes are already widely used to treat cancer, 65,66 and thus they might serve as potential therapeutic agents to suppress somatic-variant-activated MLBMs and ultimately neurodegeneration in AD.”
Wang, P., Song, X., Utpatel, K., Shang, R., Yang, Y. M., Xu, M. M., Zhang, J., Che, L., Gordan, J. D., Cigliano, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1389-4 · Cited by 17
Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation
Houde, N., Beuret, L., Bonaud, A., Fortier-Beaulieu, S.-P., Truchon-Landry, K., Aoidi, R., Pic, É., Alouche, N., Rondeau, V., Schlecht‐Louf, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110223 · Cited by 16
A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
Ross, B. D., Jang, Y., Welton, A. R., Bonham, C. A., Palagama, D. S. W., Heist, K., Boppisetti, J., Imaduwage, K. P., Robison, T. H., King, L. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32486-8 · Cited by 16
Genomics and Epigenomics in the Molecular Biology of Melanoma—A Prerequisite for Biomarkers Studies
Zob, D., Augustin, I. G., Caba, L., Pânzaru, M.-C., Popa, S., Popa, A. D., Florea, L., & Gorduza, E. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010716 · Cited by 16
“They function specifically in the MAPK/ERK cascade and determine the activation of MAPK3/ERK1 and MAPK1/ERK2 and further transduction of the signal within the MAPK/ERK cascade [53].”
BackgroundCai, D., Tian, F., Wu, M., Tu, J., & Wang, Y. (2024) · Journal of Cancer · doi:10.7150/jca.92473 · Cited by 16
A quantitative model of developmental RTK signaling
Goyal, Y., Schüpbach, T., & Shvartsman, S. Y. (2018) · Developmental Biology · doi:10.1016/j.ydbio.2018.07.012 · Cited by 17
“The importance of the negative feedback mechanisms is becoming increasingly appreciated in studies of human cancers, where negative feedbacks have been proposed to cause the activating effects of pharmacological inhibitors of the Ras signaling (Caunt et al., 2015).”
BackgroundZoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers
Dai, X., Xia, H., Zhou, S., Tang, Q., & Bi, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.022 · Cited by 17
Wang, H., Chi, L., Yu, F., Dai, H., Si, X., Gao, C., Wang, Z., Liu, L., Zheng, J., Ke, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116922 · Cited by 17
NMR in integrated biophysical drug discovery for RAS: past, present, and future
Marshall, C. B., KleinJan, F., Gebregiworgis, T., Lee, K., Fang, Z., Eves, B. J., Liu, N. F., Gasmi-Seabrook, G. M. C., Enomoto, M., & Ikura, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00338-6 · Cited by 16
Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02727-2 · Cited by 15
Lu, J. G., Hu, M., Zhao, Y., Chu, T., Zhang, W., Zhou, Y., Cai, X., Wu, J., Hu, L., Shi, C., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02382-w · Cited by 16
MEK1/2 activity modulates TREM2 cell surface recruitment
Schapansky, J., Grinberg, Y. Y., Osiecki, D. M., Freeman, E. A., Walker, S. G., Karran, E. H., Gopalakrishnan, S. M., & Talanian, R. V. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014352 · Cited by 15
“2, A–B), similar to the IC50 values of these compounds for MEK1 enzyme (41).”
BackgroundAllosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico
Fleischmann, J., Feichtner, A., DeFalco, L., Kugler, V., Schwaighofer, S., Huber, R. G., & Stefan, E. (2021) · Biomolecules · doi:10.3390/biom11040518 · Cited by 14
“, MEK1 at the positions S218 and S222 of the kinase activation loop [8,9].”
BackgroundInfluentialStructure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation
Nakae, S., Kitamura, M., Fujiwara, D., Sawa, M., Shirai, T., Fujii, I., & Tada, T. (2021) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x21011687 · Cited by 14
Targeting MEK in non-small cell lung cancer
Lara, M. S., Blakely, C. M., & Riess, J. W. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101065 · Cited by 15
Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic
Wang, Y., Xu, G., & Xia, H. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf178 · Cited by 15
Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
Temblador, A., Topalis, D., Andreï, G., & Snoeck, R. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200244 · Cited by 15
“The former showed good activity against MCC [20] and is currently under clinical investigation (NCT02514824) while the latter is used in combination with dabrafenib (a BRAF inhibitor) for the treatment of patients with BRAFV600E/K-mutant metastatic melanoma [29,30].”
MethodLi, M., Chen, L., Qu, Y., Sui, F., Yang, Q., Ji, M., Shi, B., Chen, M., & Hou, P. (2017) · Oncotarget · doi:10.18632/oncotarget.16751 · Cited by 14
“Their inhibitors have recently been approved or are currently undergoing clinical trials, and exhibited potent antitumor activity [19, 20].”
BackgroundHamis, S., Kapelyukh, Y., McLaren, A. W., Henderson, C. J., Wolf, C. R., & Chaplain, M. A. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01565-w · Cited by 14
Gu, Y., Wei, C., Chung, M., Li, H., Guo, Z., Long, M., Li, Y., Wang, W., Aimaier, R., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910505 · Cited by 16
Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
Wu, J., Chen, Y., Li, R., Guan, Y., Chen, M. H., Yin, H., Yang, X., Jin, M., Huang, B., Ding, X., et al. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202203005 · Cited by 18
“…activation by the RAS – RAF – MEK kinases cascade, ERK1/2 phosphorylates downstream effectors to participate in the regulation of numerous physiological processes, including cell adhesion, transcription, survival, proliferation, growth, and differentiation (Caunt et al., 2015; Roskoski Jr, 2012).”
Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells
Shah, H., Hill, T. A., Lim, J., & Fairlie, D. P. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00791-6 · Cited by 18
“MEK1/2 are primary kinases that activate ERK1/2 phosphorylation leading to proliferation, differentiation and survival in cancer (Caunt et al. 2015).”
BackgroundLu, X., Yu, R., Li, Z., Yang, M., Dai, J., & Liu, M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216517 · Cited by 14
Urasaki, Y., Fiscus, R. R., & Le, T. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-28335-8 · Cited by 13
The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors
Luo, Z.-K., Chen, Q., Qu, X., & Zhou, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216161 · Cited by 16
PML-II regulates ERK and AKT signal activation and IFNα-induced cell death
Meng, X., Chen, Y., Macip, S., & Leppard, K. N. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00756-5 · Cited by 15
Mai, A., Ye, S., Tu, J., Gao, J., Kang, Z., Yao, Q., & Ting, W. (2022) · Environmental Toxicology · doi:10.1002/tox.23664 · Cited by 12
“A combination of trametinib (MEK1/2 inhibitor) and GDC-0623 (MEK1 inhibitor) is required for the clinical inhibition of RAS/RAF/ERK.(9) Recently, clinical”
BackgroundEsposito, M. T. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000195 · Cited by 11
Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs
Bousoik, E., Nabiee, R., Amirrad, F., Nichols, A., Witt, R., Mahdipoor, P., & Aliabadi, H. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01070 · Cited by 13
“Mutations in KRAS, BRAF, MEK1, or MEK2 result in growth factor-independent ERK1 and ERK2 activation, which enhances cell proliferation and survival (17).”
BackgroundSynthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 16
“The limited efficacy of these inhibitors is likely explained by the rapid development of multiple feedback mechanisms that are able to re-activate the MAPK pathway at different signaling levels [73,74].”
BackgroundGu, Y., Wang, W., Li, Y., Li, H., Guo, Z., Wei, C., Long, M., Chung, M., Aimaier, R., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903177 · Cited by 16
AlZahrani, W. M., AlGhamdi, S. A., Sohrab, S. S., & Rehan, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054446 · Cited by 12
“(Asp-Phe-Gly) [6,8], that inhibitors can bind to in an ATP-noncompetitive way and can lock the protein in an inactive state, which gives higher selectivity than any other kinase targets [9].”
BackgroundChaudhary, U., Kumar, P., Sharma, P., Chikara, A., Barua, A., Mahiya, K., Subin, J. A., Yadav, P. N., & Pokharel, Y. R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107872 · Cited by 14
Liu, Y., Kang, L., Shi, S., Li, B., Zhang, Y., Zhang, X., Guo, X., Fu, G., Zheng, G., Hao, H., et al. (2022) · Neoplasma · doi:10.4149/neo_2022_211118n1640 · Cited by 12
Interaction of tRNA with MEK2 in pancreatic cancer cells
Wang, X., Chow, C. R., Ebine, K., Lee, J., Rosner, M. R., Pan, T., & Munshi, H. G. (2016) · Scientific Reports · doi:10.1038/srep28260 · Cited by 12
“In the case of using MEK2 inhibitor trametinib or U0126 7,30,31 , wild type and mutant MEK2 (P128Q) were tested for kinase activity in kinase buffer with or without inhibitor (10 μ M), in the presence or absence of yeast tRNA (2 μ g/ μ l).”
Kubin, T., Çetinkaya, A., Schönburg, M., Beiras-Fernández, A., Walther, T., & Richter, M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.02.003 · Cited by 12
“Since MEK1/2 is regarded as the „master gatekeeper” [3] of many biological and pathological processes the Ras/Raf/MEK/ERK pathway is one of the most studied signaling cascades.”
BackgroundDephosphorylation‐induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling
Ning, S., & Ma, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28540 · Cited by 13
Wang, C., Chen, Z., Nie, L., Tang, M., Feng, X., Su, D., Zhang, H., Xiong, Y., Park, J.-M., & Chen, J. (2020) · Oncogenesis · doi:10.1038/s41389-020-00271-1 · Cited by 13
Wang, S., Li, B., Shen, X., Duan, H., Guo, Z., Li, X., & Sun, F. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00690-0 · Cited by 13
Erk phosphorylation reduces the thymoquinone toxicity in human hepatocarcinoma
Zhang, B., Ting, W., Gao, J., Kang, Z., Huang, C., & Weng, Y.-J. (2021) · Environmental Toxicology · doi:10.1002/tox.23317 · Cited by 12
“suggests the need for a stronger Ras-MEK1/2-Erk blocker, either single or in combination.(24,25) Notably, inhibition of Ras-Mek1/2-Erk signaling may also lead to anti-aging intervention benefits.”
BackgroundMethodCo-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells
Winkler, M., Friedrich, J., Boedicker, C., & Dolgikh, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101313 · Cited by 15
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27335 · Cited by 11
“From our data we propose that drug resistance may represent an apoptotic by-pass pathway [19], and/or an adaptive resistance mechanism [16, 40, 41] which is dependent on PTPRS activity.”
BackgroundDai, C., Shen, L., Jin, W., Lv, B., Liu, P., Wang, X., Yin, Y., Fu, Y., Liang, L., Ma, Z., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115273 · Cited by 11
Datta, I., Vassel, T., Linkous, B. K., Odum, T., Drew, C., Taylor, A., & Bangi, E. (2023) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkad053 · Cited by 11
Lee, Y., & Lee, S.-H. (2022) · BioMed Research International · doi:10.1155/2022/7626405 · Cited by 11
“The important role of the RAF/MEK/ ERK pathway in promoting the Warburg-like e ff ects in cancer has been further studied in in vitro and in vivo mouse models [7, 8].”
RetractedDochi, T., Akita, A., Kishimoto, N., Takamune, N., & Misumi, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.177 · Cited by 13
Claas, A., Atta, L., Gordonov, S., Meyer, A. S., & Lauffenburger, D. A. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0542-y · Cited by 14
Wang, F., Wanggou, S., Cao, H., Jiang, N., Yang, Q., Huang, Q., Huang, C., & Li, X. (2020) · 癌症:英文版 · doi:10.1002/cac2.12092 · Cited by 12
“In addition to uveal melanoma, AstraZeneca is also investigating selumetinib in the treatment of KRAS-mutated lung cancer and thyroid cancer in a phase III trial [45] and of type I neurofibroma in children in a phase II clinical study [46].”
BackgroundAntigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers
Li, X., Feng, Y. C., Hou, Q., Fu, Y., & Luo, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137168 · Cited by 12
“MEK inhibitors were reported to inhibit ERK activation and its downstream processes leading to inhibitions of the proliferation of tumor cells [27].”
BackgroundChen, W., Lin, G.-B., Kuo, Y.-Y., Hsieh, C.-H., Lu, C., Sun, Y., & Chao, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250491 · Cited by 11
“431 Effect of PD98059 on the H-LIPEF activated ERK pathway and 432 protective effect 433 To confirm the neuroprotective effect of H-LIPEF is related to the ERK pathway, we inhibited 434 the MAPK kinases MEK1 and MEK2, the upstream kinases of ERK, by the inhibitor PD98059 435 [22] in the study.”
MethodKinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12
“Inhibitors against MEK and BRAF are being developed and utilised, particularly in the context of melanoma (Hauschild et al., 2012; Caunt et al., 2015).”
BackgroundMukherjee, S., Roy, S., Mukherjee, S., Harikishore, A., Bhunia, A., & Mandal, A. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105725 · Cited by 10
“Despite the tremendous potential, direct RAF inhibition has limitations since RAF inhibitors transactivate RAF dimers and stimulate the MAPK pathway, resulting in drug resistance and tumor relapse (47 – 49).”
BackgroundOnoprienko, A., Bartl, T., Grimm, C., Concin, N., & Polterauer, S. (2024) · Cancers · doi:10.3390/cancers16193268 · Cited by 14
“Allosteric inhibitors of MEK1/2 activity have the potential to effectively disrupt downstream signaling, thereby inhibiting MAPK pathway signaling and deriving tumors of growth signals [80].”
BackgroundWu, X., Guan, X., Cheng, C., Deng, Z., Zeng, L., Ma, Y., Xie, Y., & Zheng, Q. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01274-7 · Cited by 13
“Furthermore, in cancer treatment, nonselective MEK1/2 inhibitors cause more adverse effects than do selective MEK1 or MEK2 inhibitors (Caunt et al. 2015).”
Molecular mechanisms underlying cellular effects of human MEK1 mutations
Marmion, R. A., Yang, L., Goyal, Y., Jindal, G. A., Wetzel, J. L., Singh, M., Schüpbach, T., & Shvartsman, S. Y. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-10-0625 · Cited by 9
“First, since multiple components of the ERK cascade, including MEK, are drug targets in oncology and other therapeutic areas, it is critical to determine how the effects of candidate drugs are impacted by mutations (Ohren et al., 2004; Caunt et al., 2015).”
BackgroundLanghammer, S., & Scheerer, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16674 · Cited by 9
“Inhibition of MEK relieves this feedback inhibition and renders AKT signaling more active which could explain why simple MEK inhibition did not achieve pronounce changes in progression free survival [71,72].”
BackgroundDiscovery of Inactive Conformation-Selective Kinase Inhibitors by Utilizing Cascade Assays
Wang, W., Krosky, D. J., & Ahn, K. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00521 · Cited by 10
Trametinib downregulates survivin expression in RB1-positive KRAS -mutant lung adenocarcinoma cells
Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Niki, T., Takahashi, H., & Sakuma, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.230 · Cited by 10
Rittler, D., Molnár, E., Baranyi, M., Garay, T., Hegedüs, L., Aigner, C., Tóvári, J., Tímár, J., & Hegedűs, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207649 · Cited by 14
“MEK1/2 serves as a gatekeeper in the RAS/RAF pathway being an exclusive activator of Erk, therefore, MEK inhibition is a promising way to successfully block the downstream elements of the cascade [12].”
BackgroundFast Mek1 Hit Identification with TRIC Technology Correlates Well with Other Biophysical Methods
Jeridi, S., Rak, A., Gupta, A. J., & Soule, P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211026267 · Cited by 10
“26(8) 1014 –1019 © Society for Laboratory Automation and Screening 2021 DOI: 10 1177/24725552211026267 journals.”
Gong, K.-Q., Mikacenic, C. R., Long, M. E., Frevert, C. W., Birkland, T. P., Charron, J., Gharib, S. A., & Manicone, A. M. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0252oc · Cited by 10
mCAUSE: Prioritizing mitochondrial targets that alleviate pancreatic cancer cell phenotypes
Murata, D., Ito, F., Tang, G., Iwata, W., Yeung, N., West, J. J., Ewald, A. J., Wang, X., Iijima, M., & Sesaki, H. (2024) · iScience · doi:10.1016/j.isci.2024.110880 · Cited by 9
Therapeutic Treatment Options for In-Transit Metastases from Melanoma
Russano, F., Rastrelli, M., Dall’Olmo, L., Fiore, P. D., Gianesini, C. M., Vecchiato, A., Mazza, M., Tropea, S., & Mocellin, S. (2024) · Cancers · doi:10.3390/cancers16173065 · Cited by 13
“MEK inhibitors target downstream enzymes in the MAPK/ERK pathway, further inhibiting cancer cell proliferation [48].”
BackgroundBanimohammad, M., Khalafi, P., Gholamin, D., Bangaleh, Z., Akhtar, N., Solomon, A. D., Prabhakar, P. K., Sanami, S., Prakash, A., & Pazoki–Toroudi, H. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002306 · Cited by 12
Targeting pathological ERK1/2 signaling in cancer and beyond
Schanbacher, C., Goebeler, M.-E., Gerull, B., & Lorenz, K. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.08.001 · Cited by 15
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 10
“In addition, as MAPK pathway activity phosphorylates and negatively regulates upstream activators of RAS, including RTKs, such as EGFR and FGFR (37), KRAS inhibitor treatment is likely to lead to enhanced RTK activity therefore driving adaptive feedback.”
Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma
Pomella, S., Porrazzo, A., Cassandri, M., Camero, S., Codenotti, S., Milazzo, L., Vulcano, F., Barillari, G., Cenci, G., Marchese, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113281 · Cited by 9
Deng, L., Huang, X., Dong, C., & Ren, J. (2021) · The Analyst · doi:10.1039/d1an00090j · Cited by 9
Matching anticancer compounds and tumor cell lines by neural networks with ranking loss
Prasse, P., Iversen, P., Lienhard, M., Thedinga, K., Bauer, C., Herwig, R., & Scheffer, T. (2022) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab128 · Cited by 10
“The compound is currently investigated in combination with other compounds for the treatment of patients with BRAFV600E metastatic colon cancer (33).”
BackgroundMondru, A. K., Wilkinson, B., Aljasir, M. A., Alrumayh, A., Greaves, G., Emmett, M. S., Albohairi, S. H., Pritchard‐Jones, R., & Cross, M. J. (2024) · FEBS Letters · doi:10.1002/1873-3468.14960 · Cited by 9
“Combinations of BRAF and MEK inhibitors have been utilised clinically in an attempt to reinforce inhibition of the ERK1/2 signalling axis in BRAFV600E melanoma cells [10,43].”
Long, M. E., Gong, K.-Q., Eddy, W. E., Liles, W. C., & Manicone, A. M. (2017) · Pneumonia · doi:10.1186/s41479-017-0037-y · Cited by 9
“The mitogen-activated protein kinases MEK1 (Map2k1) and MEK2 (Map2k2) participate in intracellular signaling networks and exert control on the downstream effector molecules ERK1 and ERK2, via MEK1/2-dependent serine and tyrosine phosphorylation [2].”
BackgroundDodd, R. D., Scherer, A., Huang, W., McGivney, G. R., Gutierrez, W. R., Laverty, E. A., Ashcraft, K. A., Stephens, V. R., Yousefpour, P., Saha, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2597 · Cited by 10
“In addition, PI3K signaling can modulate cross-talk with theMAPK/ERKandmTOR/S6 pathways (35, 36).”
BackgroundOptically Activated MEK1/2 Inhibitors (Opti-MEKI) as Potential Antimelanoma Agents
Hao, C., Li, X., Wang, Z., Liu, L., He, F., & Pan, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115236 · Cited by 12
Tatsumoto, N., Saito, S., Rifkin, I. R., Bonegio, R. G. B., Leal, D. N., Sen, G. C., Arditi, M., & Yamashita, M. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100190 · Cited by 8
PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma
Zhao, B., Fang, R., Schürmann, H., Hemmer, E. J., Mayer, G. L., Trajkovic-Arsic, M., Althoff, K., Yang, J., Godfrey, L., Liffers, S. T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115541 · Cited by 10
Advances in osteosarcoma research: Pathogenesis and emerging therapeutic strategies
Yan, L. ‐., Dong, X., & Chen, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105252 · Cited by 11
Mechanism of kinetin-induced death of Vicia faba ssp. minor root cortex cells
Kaźmierczak, A., Kunikowska, A., Doniak, M., & Kornaś, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03103-3 · Cited by 8
Mushtaq, H., Zarlashat, Y., Ambreen, A., Mujahid, M., & Shafqat4, S. K. A. D. (2024) · Agrobiological Records · doi:10.47278/journal.abr/2024.004 · Cited by 11
MEK inhibitors in oncology: a patent review and update (2016 – present)
Suryavanshi, A., Vandana, Shukla, Y. K., Kumar, V., Gupta, P., Asati, V., Mahapatra, D. K., Keservani, R. K., Jain, S. K., & Bharti, S. K. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2403634 · Cited by 17
“Genes linked to the cell cycle are transcriptionally modified as a result of MAPK’s modification of transcription factor levels and activities [3–6].”
Sinus pericranii, skull defects, and structural brain anomalies in TRAF7 ‐related disorder
Accogli, A., Scala, M., Pavanello, M., Severino, M., Gandolfo, C., Marco, P. D., Musacchia, F., Torella, A., Pinelli, M., Nigro, V., et al. (2020) · Birth Defects Research · doi:10.1002/bdr2.1711 · Cited by 7
Giannopoulou, A. F., Velentzas, A. D., Anagnostopoulos, A. K., Agalou, A., Papandreou, N. C., Katarachia, S. A., Koumoundourou, D. G., Konstantakou, E. G., Pantazopoulou, V. I., Delis, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13092024 · Cited by 8
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
Catalano, A., Adlesic, M., Kaltenbacher, T., Klar, R. F. U., Albers, J., Seidel, P., Brandt, L. P., Hejhal, T., Busenhart, P., Röhner, N., et al. (2021) · Cancers · doi:10.3390/cancers13081852 · Cited by 11
Trametinib enhances ATRA-induced differentiation in AML cells
Lü, H., Li, Z.-Y., Ding, M., Cui, L., Weng, X., Sheng, Y., Wu, J., & Cai, X. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1961231 · Cited by 9
Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
Chilamakuri, R., & Agarwal, S. (2022) · Current Oncology · doi:10.3390/curroncol29090512 · Cited by 9
“MEK1/2 acts as a gatekeeper for the Ras-MEK-ERK pathway and transmits signals from multiple upstream regulators to the ERK1/2 [41].”
BackgroundInfluentialAnalysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases
Romany, A., Liu, R., Zhan, S., Clayton, J., & Shen, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00014 · Cited by 8
Luo, G., Feng, R., Sun, Y., Zheng, L., Wang, Y., Chen, Y., & Wen, T. (2018) · Oncology Reports · doi:10.3892/or.2018.6796 · Cited by 8
“To gain deeper insight into the mechanisms by which DCF1 controls cell viability, motility and apoptosis in N2a cells and SK-N-SH cells, we focused on the mitogen-activated protein kinase (MAPK) cascade pathway since previous studies have indicated that the activation or inhibition of the classical MAPK pathway (or th…”
Zhang, H., Read, A., Cataisson, C., Yang, H. H., Lee, W., Turk, B. E., Yuspa, S. H., & Luo, J. (2024) · Science Signaling · doi:10.1126/scisignal.add5073 · Cited by 8
“Whereas BRAF - mutant melanomas are often highly sensitive to BRAF and MAPK kinase (MEK) inhibitors ( 7 ), RAS - mutant tumors are generally much less sensitive to MAPK pathway inhibition ( 11 ).”
BackgroundTargeting MXD1 sensitises pancreatic cancer to trametinib
Zhang, S., Deng, S., Liu, J., Liu, S., Chen, Z., Liu, S., Xue, C., Zeng, L., Zhao, H., Xu, Z., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333408 · Cited by 7
Jiang, H., Satoh, Y., Yamamura, R., Ooshio, T., Luo, Y., Hai, H., Otsuka, T., Hata, S., Sato, R., Hirata, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.037 · Cited by 10
Dong, L., Choi, H., Budhu, S., Schulze, I., Verma, S., Mangarin, L. M. B., Navarro, V. E., Mehanna, N., Khan, J. F., Venkatesh, D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0729 · Cited by 7
Zhuang, H., Han, S., Harris, N., & Reeves, W. H. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42936 · Cited by 8
“EGR-1 is a transcription factor downstream of MEK1/2 that regulates coagulation, in fl ammation, vascular permeability, and apoptosis 25,26 and plays a central role in lung ischemia-perfusion injury.”
A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2
Iijima, M., Kubota, Y., Sawa, R., Kubota, Y., Hatano, M., Igarashi, M., Kawada, M., Momose, I., Takekawa, M., & Shibasaki, M. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.100 · Cited by 7
Li, P., Liu, P., Peng, Y., Zhang, Z.-H., Li, X., Xiong, R., Chen, X., Zhao, Y., Ning, Y., Yang, N., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1480221 · Cited by 7
“Although it has been reported that ERK1/2 can also regulate proliferation through ETS family members and other pathways [30,31], the degree and consistency of c-Ski expression and proliferation effects upon TGF-β1 treatment with MEK inhibition in this Figure 3.”
BackgroundResistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
Sale, M. J., Balmanno, K., & Cook, S. J. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.14 · Cited by 8
“Several of these have proven successful in the clinic, including the MEK1/2 inhibitors (MEKi) trametinib and cobimetinib, and the BRAF inhibitors (BRAFi) vemurafenib and dabrafenib, all of which are approved for the treatment of BRAF-mutant melanoma([1,2]).”
BackgroundSelf-citationStat2 loss disrupts damage signalling and is protective in acute pancreatitis
Heath, H., Britton, G., Kudo, H., Renney, G., Ward, M. A., Hutchins, R., Foster, G. R., Goldin, R. D., & Alazawi, W. (2020) · The Journal of Pathology · doi:10.1002/path.5481 · Cited by 7
“Five out of 6 significantly identified pathways contain at least one mitogen-activated protein (MAP) kinases, including MAP2K2 (MEK2), the principal activator of extracellular signal related kinases (ERK1 and ERK2, [14]).”
BackgroundMek1 and Mek2 Functional Redundancy in Erythropoiesis
Beuret, L., Fortier-Beaulieu, S.-P., Rondeau, V., Roy, S., Houde, N., Balabanian, K., Espéli, M., & Charron, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639022 · Cited by 7
“As such, MEK proteins have been considered potential therapeutic targets as overactivation of ERK pathway is observed in many cancers (Zhao and Adjei, 2014; Caunt et al., 2015).”
BackgroundZhao, L., Zhang, Y., Li, A., Lu, X., Li, M., Yuan, Q., Yang, N., Zhao, X., Li, X., Jiang, Y., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.09.007 · Cited by 7
Rosa, J., Myskiw, J. D. C., Fiorenza, N. G., Furini, C. R. G., Sapiras, G. G., & Izquierdo, I. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114129 · Cited by 11
Carrillo, P., Bernal, M., Tellez-Quijorna, C., Marrero, A. D., Vidal, I., Castilla, L., Caro, C., Domínguez, A., García‐Martín, M. L., Quesada, A. R., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114070 · Cited by 7
“MLK1 (also known as MAP3K9 or MEKK9) is a protein kinase involved in signal transduction that is frequently expressed in certain cancer types, as is the case of melanoma and breast cancer [21,22] and is located upstream of different signalling axes such as ERK1/2 MAPK, among others [23].”
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.